| 14.945 -0.555 (-3.58%) | 05-04 11:46 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 20.14 | 1-year : | 23.53 |
| Resists | First : | 17.25 | Second : | 20.14 |
| Pivot price | 14.78  |
|||
| Supports | First : | 10.5 | Second : | 6.34 |
| MAs | MA(5) : | 14.3 |
MA(20) : | 13.94 |
| MA(100) : | 7.35 |
MA(250) : | 3.91 |
|
| MACD | MACD : | 1.4 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 78.5 |
D(3) : | 71.7 |
| RSI | RSI(14): 61.9 |
|||
| 52-week | High : | 17.25 | Low : | 0.87 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ANL ] has closed below upper band by 35.6%. Bollinger Bands are 13.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.95 - 16.02 | 16.02 - 16.08 |
| Low: | 12.88 - 12.93 | 12.93 - 12.99 |
| Close: | 15.39 - 15.51 | 15.51 - 15.62 |
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
Fri, 01 May 2026
H.C. Wainwright Sees “Potential Best-in-Class Potency” for Adlai Nortye’s (ANL) Lead Asset, Lifts PT - Insider Monkey
Wed, 29 Apr 2026
Adlai Nortye: Recapitalized, Refocused, But Still Too Early To Upgrade (NASDAQ:ANL) - Seeking Alpha
Wed, 29 Apr 2026
Adlai Nortye (ANL) director Ji Ping submits Form 3 insider report - Stock Titan
Wed, 29 Apr 2026
[EFFECT] Adlai Nortye Ltd. SEC Filing - Stock Titan
Mon, 27 Apr 2026
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Update - MarketBeat
Fri, 17 Apr 2026
Adlai Nortye (NASDAQ:ANL) Stock Price Up 18.1% - What's Next? - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 59 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 5.6 (%) |
| Held by Institutions | 6.9 (%) |
| Shares Short | 2,290 (K) |
| Shares Short P.Month | 1,070 (K) |
| EPS | -1.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.21 |
| Profit Margin | 0 % |
| Operating Margin | -330.5 % |
| Return on Assets (ttm) | -42.3 % |
| Return on Equity (ttm) | -414.1 % |
| Qtrly Rev. Growth | 178.1 % |
| Gross Profit (p.s.) | 0.08 |
| Sales Per Share | 0.08 |
| EBITDA (p.s.) | -0.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -13.97 |
| PEG Ratio | 0 |
| Price to Book value | -73.84 |
| Price to Sales | 182.12 |
| Price to Cash Flow | -27.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|